WAM
PRTK

Wolverine Asset Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Wolverine Asset Management’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-592
Closed -$21K – 2918
2013
Q2 		$21K Buy
+592
New +$25.4K ﹤0.01% 1999

Other funds holding PRTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
APCM
Arbiter Partners Capital Management New York $175M AUM 99.81% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Wolverine Asset Management's PRTK Position: Q3 2013 in Review

Wolverine Asset Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2013, closing a stake of 592 shares — an estimated $21K sold.

Wolverine Asset Management first reported a position in PRTK in Q2 2013 and held it in 1 quarter. The position peaked at $21K in Q2 2013. 42 funds tracked by Wall St. Rank hold PRTK as of Q3 2013.

  • Wolverine Asset Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2013 after selling out during the quarter.
  • Wolverine Asset Management sold 592 Paratek Pharmaceuticals, Inc. shares in Q3 2013, an estimated $21K.
  • Wolverine Asset Management first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2013 and held it in 1 quarter.
  • Wolverine Asset Management's Paratek Pharmaceuticals, Inc. position peaked at $21K in Q2 2013.
  • 42 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2013.

Based on Wolverine Asset Management's 13F filing for Q3 2013, filed 13 Nov 2013.